Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Gamida Cell ltd
Information provided by (Responsible Party):
Gamida Cell ltd Identifier:
First received: March 19, 2013
Last updated: September 15, 2016
Last verified: September 2016
A Study Evaluating the Safety and Efficacy of Transplantation of a single cord blood unit (CBU) of NiCord®, umbilical cord blood-derived Ex Vivo Expanded Stem and Progenitor Cells in Patients with Hematological Malignancies.

Condition Intervention Phase
Hematological Malignancies
Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Drug: NiCord®
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies

Resource links provided by NLM:

Further study details as provided by Gamida Cell ltd:

Primary Outcome Measures:
  • Engraftment [ Time Frame: 42 days ]
    Assess the cumulative incidence of patients with NiCord®-derived neutrophil engraftment at 42 days following transplantation.

Estimated Enrollment: 40
Study Start Date: April 2013
Estimated Study Completion Date: March 2018
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NiCord®
NiCord® is a stem/progenitor cell based product composed of ex vivo expanded allogeneic UCB cells.
Drug: NiCord®

Detailed Description:

Umbilical cord blood (UCB) is an alternative stem cell source for hematopoietic stem cell transplantations (HSCT) and can be used for the treatment of various life-threatening diseases, such as hematological malignancies or genetic blood disorders, in such cases where a matched related stem cell donor is not available. However, the major drawback of using this valuable stem cells source is the limited cell dose in a single cord blood unit (CBU), which was shown to be associated with inadequate hematopoietic reconstitution and high risk of transplant-related mortality. To improve outcomes and extend applicability of UCB transplantation, one potential solution is ex vivo expansion of UCB-derived stem and progenitor cells. NiCord® is a stem/progenitor cell based product composed of ex vivo expanded allogeneic UCB cells. NiCord® is based on a novel technology for the ex vivo cell expansion of cord blood derived hematopoietic progenitor cells. By increasing the number of the short and long-term reconstitution progenitor cells transplanted, NiCord® has the potential to enable the broader application of UCB transplantation, and improve the clinical outcomes of UCB transplantation.

The study is designed as a multi center, single arm study, evaluating the safety and efficacy of the transplantation of NiCord® to patients with hematological malignancies following myeloablative therapy.

Total study duration is approximately 400 days from the signing of informed consent to the last visit one year following transplantation

The overall study objective is to evaluate the safety and efficacy of NiCord®: single ex-vivo expanded cord blood unit transplantation in patients with hematological malignancies following myeloablative therapy as follows:

The main study objectives are to assess the cumulative incidence of patients with NiCord®-derived neutrophil engraftment at 42 days following transplantation and to assess the incidence of secondary graft failure at 180 days following transplantation of NiCord® Ten evaluable patients recruited for the study should be 18-65 years of age, up to a maximum of 15 treated patients.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Applicable disease and eligible for myeloablative SCT
  • Patients must have two partially HLA-matched CBUs
  • Back-up stem cell source
  • Adequate Karnofsky Performance score or Lansky Play-Performance scale
  • Sufficient physiological reserves
  • Signed written informed consent

Exclusion Criteria:

  • HLA-matched donor able to donate
  • Prior allogeneic HSCT
  • Other active malignancy
  • Active or uncontrolled infection
  • Active/symptoms of central nervous system (CNS) disease
  • Pregnancy or lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01816230

Contact: Iddo Peleg, MSc. MBA +972-2-659-5630

United States, California
Cedars-Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact: Michael Lill, MD    310-423-1160      
Principal Investigator: Michael Lill, MD         
United States, New York
Steven and Alexandra Cohen Children's Medical Center Recruiting
New York, New York, United States, 11040
Contact: Joel Brochstein, MD    718-470-3460      
Principal Investigator: Joel Brochstein, MD         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Mitchell Horwitz, MD    919-668-1045   
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Contact: Navneet Majhail, MD    216-444-2199      
Principal Investigator: Navneet Majhail, MD         
United States, Oregon
Oregon Health & Science University Not yet recruiting
Portland, Oregon, United States, 97239
Contact: Richard Maziarz, MD    503-494-4606      
Principal Investigator: Richard Maziarz, MD         
United States, Tennessee
Vanderbilt Recruiting
Nashville, Tennessee, United States, 37240
Contact: Madan Jagasia, MD    615-936-8422      
Principal Investigator: Madan Jagasia, MD         
Children Hospital Gaslini Scientific Institute Recruiting
Genoa, Italy, 16147
Contact: Francesco Frassoni, MD    +39 (010) 563669      
Principal Investigator: Francesco Frassoni, MD         
University of Turin Recruiting
Turin, Italy, 10043
Contact: Daniela Cilloni, MD    +39 0116705475      
Principal Investigator: Daniela Cilloni, MD         
University Medical Center Utrecht Recruiting
Utrecht, Netherlands, 3503 AB
Contact: Jaap Jan Boelens, MD    +31-88-7554003      
Principal Investigator: Jaap Jan Boelens, MD         
University Hospital Vall d´Hebron Recruiting
Barcelona, Spain, 08035
Contact: David Valcárcel, MD    34 (934) 893 000 ext 6417      
Principal Investigator: David Valcárcel, MD         
Hospital Universitario La Fe Recruiting
Valencia, Spain, 46009
Contact: Guillermo Sanz, MD    +34 (96) 386-2709      
Principal Investigator: Guillermo Sanz, MD         
Sponsors and Collaborators
Gamida Cell ltd
Principal Investigator: Mitchell Horwitz, MD Duke University
  More Information

Responsible Party: Gamida Cell ltd Identifier: NCT01816230     History of Changes
Other Study ID Numbers: GC P#03.01.020
Study First Received: March 19, 2013
Last Updated: September 15, 2016

Additional relevant MeSH terms:
Leukemia, Myeloid, Acute
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Leukemia, Myeloid
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions processed this record on April 26, 2017